U
User.45
Guest
Yes, source or GTFO. How come you can't live up to the most minimal standards of discourse a on serious topic?!At the time we got it, we had 2 shots. And given the CDC is now implying that at least with Delta, natural immunity is better, we probably won't get the 3rd unless required. But those requirements seem to be going away as well.
in the meantime, the paper above you didn't read concludes this:
In this study, we showed that mRNA vaccinated blood donors have a median of 17 times higher RBD antibody levels when compared with those who became seropositive due to prior COVID-19. Our results indicated an exceptional strong association between high RBD antibody levels in and the ability to biochemically neutralize RBD binding to the cellular ACE2 receptor. The N501Y mutation, while did not alter the neutralizing antibody binding, presented with a fivefold greater affinity to ACE2, which resulted in a drastically reduced ability of COVID-19 convalescent antisera to neutralize its ACE2 binding. Fortunately, the vaccinated blood samples, due to their much-elevated RBD antibody levels, were far more effective in neutralizing both the WT and N501Y RBD from binding to ACE. With an average of 16-fold greater potency than convalescent blood, the vaccinated blood samples were more than sufficient to compensate for the fivefold increased affinity of N501Y RBD, resulting in the highly effective inhibition of both the WT and N501Y RBD from binding to ACE2.
We observed very strong correlation between RBD antibody levels and ability to biochemically neutralize RBD and ACE2 binding. Previous studies have shown the correlation between neutralizing antibody and protection34,35. With over 150 million people infected with SARS-CoV-2 by May 2021, one of the critical questions going forward is whether the natural immunity would be sufficient to prevent future reinfections, particularly by more infectious variants. N501Y RBD is central to the investigation as it is the key driver to increased affinity to cell ACE2 receptors. While the reinfections were seen with the original SARS-CoV-2, our results indicated that the antisera from natural immunity would be less effective against variants such as B.1.1.7 due to its increased affinity to ACE2. Thus, many individuals acquired immunity through prior SARS-CoV-2 infections would not be sufficient to prevent reinfections by new variants with higher affinity to their cell receptors, especially in those with low RBD antibody levels.